10-Q

UNITED STATES

securities and exchange commission

Washington D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission file number: 000-28827

______________________

PETMED EXPRESS, INC.

(Exact name of registrant as specified in its charter)

______________________

FLORIDA	65-0680967
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

420 South Congress Avenue, Delray Beach, Florida 33445

(Address of principal executive offices, including zip code)

(561) 526-4444

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ☐	Accelerated filer                    ☒
Non-accelerated filer    ☐	Smaller reporting company  ☐
(Do not check if smaller reporting company)	Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 20,685,555 Common Shares, $.001 par value per share at July 31, 2018.

PART I - FINANCIAL INFORMATION

ITEM 1.   FINANCIAL STATEMENTS.

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for per share amounts)

	June 30,		March 31,
	2018		2018
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	94,561	$	77,936
Accounts receivable, less allowance for doubtful accounts of $37 and $35, respectively		2,431		2,292
Inventories - finished goods		25,046		23,337
Prepaid expenses and other current assets		1,278		882
Prepaid income taxes		-		788
Total current assets		123,316		105,235
Noncurrent assets:
Property and equipment, net		28,491		28,741
Intangible assets		860		860
Total noncurrent assets		29,351		29,601
Total assets	$	152,667	$	134,836
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	21,182	$	15,274
Accrued expenses and other current liabilities		3,526		2,835
Income taxes payable		3,247		-
Total current liabilities		27,955		18,109
Deferred tax liabilities		831		996
Total liabilities		28,786		19,105
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share		9		9
Common stock, $.001 par value, 40,000 shares authorized; 20,601 and 20,601 shares issued and outstanding, respectively		21		21
Additional paid-in capital		10,100		9,381
Retained earnings		113,751		106,320
Total shareholders' equity		123,881		115,731
Total liabilities and shareholders' equity	$	152,667	$	134,836

See accompanying notes to condensed consolidated financial statements.

1

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except for per share amounts)(Unaudited)

	Three Months Ended
	June 30,
	2018		2017
Sales	$	87,390	$	79,657
Cost of sales		57,436		52,192
Gross profit		29,954		27,465
Operating expenses:
General and administrative		6,934		6,226
Advertising		6,707		6,292
Depreciation		556		531
Total operating expenses		14,197		13,049
Income from operations		15,757		14,416
Other income:
Interest income, net		379		83
Other, net		317		241
Total other income		696		324
Income before provision for income taxes		16,453		14,740
Provision for income taxes		3,871		5,464
Net income	$	12,582	$	9,276
Comprehensive income	$	12,582	$	9,276
Net income per common share:
Basic	$	0.62	$	0.46
Diluted	$	0.62	$	0.45
Weighted average number of common shares outstanding:
Basic		20,408		20,293
Diluted		20,449		20,448
Cash dividends declared per common share	$	0.25	$	0.20

See accompanying notes to condensed consolidated financial statements.

2

PETMED EXPRESS, INC. AND SUBSIDIARIES

condensed consolidated statementS of cash flows

(In thousands)(Unaudited)

	Three Months Ended
	June 30,
	2018			2017
Cash flows from operating activities:
Net income	$	12,582		$	9,276
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		556			531
Share based compensation		719			494
Deferred income taxes		(165	)		(104	)
Bad debt expense		32			28
(Increase) decrease in operating assets and increase in liabilities:
Accounts receivable		(171	)		(279	)
Inventories - finished goods		(1,709	)		(2,804	)
Prepaid income taxes		788			-
Prepaid expenses and other current assets		(396	)		(494	)
Accounts payable		5,908			984
Accrued expenses and other current liabilities		643			696
Income taxes payable		3,247			5,568
Net cash provided by operating activities		22,034			13,896
Cash flows from investing activities:
Purchases of property and equipment		(306	)		(43	)
Net cash used in investing activities		(306	)		(43	)
Cash flows from financing activities:
Dividends paid		(5,103	)		(4,058	)
Net cash used in financing activities		(5,103	)		(4,058	)
Net increase in cash and cash equivalents		16,625			9,795
Cash and cash equivalents, at beginning of period		77,936			58,730
Cash and cash equivalents, at end of period	$	94,561		$	68,525
Supplemental disclosure of cash flow information:
Dividends payable in accrued expenses	$	288		$	263

See accompanying notes to condensed consolidated financial statements.

3

PETMED EXPRESS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1: Summary of Significant Accounting Policies

Organization

PetMed Express, Inc. and subsidiaries, d/b/a 1-800-PetMeds (the “Company”), is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The Company offers consumers an attractive alternative for obtaining pet medications in terms of convenience, price, and speed of delivery. The Company markets its products through national advertising campaigns, which aim to increase the recognition of the “1-800-PetMeds” brand name, and “PetMeds” family of trademarks, increase traffic on its website at www.1800petmeds.com, acquire new customers, and maximize repeat purchases. The majority of the Company’s sales are to residents in the United States. The Company’s corporate headquarters and distribution facility is located in Delray Beach, Florida. The Company’s fiscal year end is March 31, and references herein to fiscal 2019 or fiscal 2018 refer to the Company's fiscal years ending March 31, 2019 and 2018, respectively.

Basis of Presentation and Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at June 30, 2018, the Statements of Comprehensive Income for the three months ended June 30, 2018 and 2017, and Cash Flows for the three months ended June 30, 2018 and 2017. The results of operations for the three months ended June 30, 2018 are not necessarily indicative of the operating results expected for the fiscal year ending March 31, 2019. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2018. The Condensed Consolidated Financial Statements include the accounts of PetMed Express, Inc. and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates

The preparation of Condensed Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, “Revenue from Contracts with Customers” (“ASC 606”). ASC 606 clarifies the accounting for revenue arising from contracts with customers and specifies the disclosures that an entity should include in its financial statements. During 2016, the FASB issued certain amendments to the standard relating to the principal versus agent guidance, accounting for licenses of intellectual property and identifying performance obligations as well as the guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The Company adopted ASC 606 using the modified retrospective method on April 1, 2018. Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods.

4

The Company evaluated only contracts not completed at the date of initial application for each of the five steps in ASC 606, which are as follows: 1) Identify the contract with the customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations; and 5) Recognize revenue when (or as) performance obligations are satisfied. The effect of initially applying ASC 606 did not result in an opening balance adjustment to retained earnings or any other Balance Sheet accounts because the Company: (1) identified similar performance obligations under ASC 606 as compared with deliverables and separate units of account previously identified; (2) determined the transaction price to be consistent; and (3) concluded that revenue is recorded at the same point in time, upon shipment under both ASC 605 and ASC 606. Additionally, the Company concluded that the accounting for fulfillment costs or costs incurred to obtain a contract is unchanged by the adoption of ASC 606. The adoption of ASC 606 did not require significant changes in our internal controls and procedures over financial reporting and disclosures. However, we made enhancements to existing internal controls and procedures to ensure compliance with the new guidance.

In February 2016, the FASB issued guidance on leases which supersedes the current lease guidance. The core principle requires lessees to recognize the assets and liabilities that arise from nearly all leases in the statement of financial position. Accounting applied by lessors will remain largely consistent with previous guidance. Additional changes are expected to align lessor accounting with the revised lessee model and the FASB’s revenue recognition guidance. The amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements. We do not expect the standard to have a material impact on our consolidated financial statements.

The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

Note 2: Revenue Recognition

The Company generates revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however not considered a key judgment. There are no amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Outbound shipping and handling fees are an accounting policy election, and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.

The Company disaggregates revenue in the following two categories: (1) Reorder revenue vs new order revenue, and (2) Internet revenue vs. contact center revenue. The following table illustrates revenue by various classifications:

Three Months Ended June 30,
Revenue (In thousands)	2018		%			2017		%			$ Variance		% Variance
Reorder Sales	$	71,501		81.8	%	$	64,465		80.9	%	$	7,036		10.9	%
New Order Sales		15,889		18.2	%		15,192		19.1	%		697		4.6	%
Total Net Sales	$	87,390		100.0	%	$	79,657		100.0	%	$	7,733		9.7	%
Internet Sales	$	74,320		85.0	%	$	66,647		83.7	%	$	7,673		11.5	%
Contact Center Sales		13,070		15.0	%		13,010		16.3	%		60		0.5	%
Total Net Sales	$	87,390		100.0	%	$	79,657		100.0	%	$	7,733		9.7	%

5

The majority of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales. The Company had no material contract asset or contract liability balances as of June 30, 2018 or March 31, 2018.

Note 3: Net Income Per Share

In accordance with the provisions of ASC Topic 260 (“Earnings Per Share”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock and convertible preferred shares issued by the Company represent the only dilutive effect reflected in the diluted weighted average shares outstanding. The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented (in thousands, except for per share amounts):

	Three Months Ended June 30,
	2018		2017
Net income (numerator):
Net income	$	12,582	$	9,276
Shares (denominator):
Weighted average number of common shares outstanding used in basic computation		20,408		20,293
Common shares issuable upon vesting of restricted stock		31		145
Common shares issuable upon conversion of preferred shares		10		10
Shares used in diluted computation		20,449		20,448
Net income per common share:
Basic	$	0.62	$	0.46
Diluted	$	0.62	$	0.45

At June 30, 2018, 77,350 shares of common restricted stock were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted net income per common share. At June 30, 2017, all common restricted stock was included in the diluted net income per common share computation.

Note 4: Stock-Based Compensation

The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Share Based Payment”) (ASU 2016-09). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses. The Company had 974,609 restricted common shares issued under the 2006 Employee Equity Compensation Restricted Stock Plan (“2006 Employee Plan”), 47,350 restricted common shares issued under the 2016 Employee Equity Compensation Restricted Stock Plan (“2016 Employee Plan” and collectively referred to with the 2006 Employee Plan as the “Employee Plans”), 272,000 restricted common shares issued under the 2006 Outside Director Equity Compensation Restricted Stock Plan (“2006 Director Plan”), and 60,000 restricted common shares issued under the 2015 Outside Director Equity Compensation Restricted Stock Plan (“2015 Director Plan”, and collectively referred to with the 2006 Director Plan as the “Director Plans”) at June 30, 2018, all shares of which were issued subject to a restriction or forfeiture period that lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over the three-year restriction period.

6

The Company did not issue any shares of restricted stock during the quarter. For the quarters ended June 30, 2018 and 2017, the Company recognized $719,000 and $494,000, respectively, of compensation expense related to the Employee and Director Plans. At June 30, 2018 and 2017, there was $3.7 million and $2.8 million of unrecognized compensation cost related to the non-vested restricted stock awards, respectively, which is expected to be recognized over the next three years. At June 30, 2018 and 2017, there were 193,000 and 232,000 non-vested restricted shares, respectively.

Note 5: Fair Value

The Company carries cash and cash equivalents and investments at fair value in the Condensed Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (“Fair Value Measurements”) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At June 30, 2018, the Company had invested the majority of its $94.6 million cash and cash equivalents balance in money market funds which are classified within level 1.

Note 6: Commitments and Contingencies

The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company initiates litigation to protect its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred.

Note 7: Changes in Shareholders’ Equity:

Changes in shareholders’ equity for the three months ended June 30, 2018 is summarized below (in thousands):

	Additional
	Paid-In		Retained
	Capital		Earnings
Beginning balance at March 31, 2018:	$	9,381	$	106,320
Share based compensation		719		-
Dividends declared		-		(5,151	)
Net income		-		12,582
Ending balance at June 30, 2018:	$	10,100	$	113,751

No shares of treasury stock were purchased or retired in the three months ended June 30, 2018 and 2017.

Note 8: Income Taxes

For the quarters ended June 30, 2018 and 2017, the Company recorded an income tax provision of approximately $3.9 million and $5.5 million, respectively. The effective tax rate for the quarter ended June 30, 2018 was approximately 23.5% compared to 37.1% for the quarter ended June 30, 2017. The decrease in the income tax provision and the effective tax rate for the quarter ended June 30, 2018 are directly related to a decrease in the federal tax rate from 35.0% to 21.0% pursuant to the Tax Cuts and Jobs Act of 2017 (“2017 Act”).

7

Note 9: Subsequent Events

On July 23, 2018, the Board of Directors declared an increased quarterly dividend of $0.27 per share. The Board established an August 3, 2018 record date and an August 10, 2018 payment date. Based on the outstanding share balance as of July 31, 2018 the Company estimates the dividend payable to be approximately $5.6 million.

On July 27, 2018, the Board of Directors approved the issuance of 47,450 restricted shares to certain employees of the Company, pursuant to the 2016 Employee Plan and the issuance of 37,500 restricted shares to the independent directors, pursuant to the 2015 Director Plan.

8

ITEM 2.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Executive Summary

PetMed Express was incorporated in the state of Florida in January 1996. The Company’s common stock is traded on the NASDAQ Global Select Market under the symbol “PETS”. The Company began selling pet medications and other pet health products in September 1996. In March 2010 the Company started offering for sale additional pet supplies on its website, and these items are drop shipped to customers by third party vendors. Presently, the Company’s product line includes approximately 3,000 SKUs of the most popular pet medications, health products, and supplies for dogs and cats.

The Company markets its products through national advertising campaigns which aim to increase the recognition of the “1-800-PetMeds” brand name, and “PetMeds” family of trademarks, increase traffic on its website at www.1800petmeds.com, acquire new customers, and maximize repeat purchases. Approximately 85% of all sales were generated via the Internet for the quarter ended June 30, 2018, compared to 84% for the quarter ended June 30, 2017. The Company’s sales consist of products sold mainly to retail consumers. The three-month average purchase was approximately $90 and $87 per order for the quarters ended on June 30, 2018 and 2017, respectively.

Critical Accounting Policies

Our discussion and analysis of our financial condition and the results of our operations are based upon our Condensed Consolidated Financial Statements and the data used to prepare them. The Company’s Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.

Revenue recognition

The Company generates revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however not considered a key judgment. There are no amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership.

Outbound shipping and handling fees are an accounting policy election, and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales. The majority of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales.

The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card charge-backs or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for doubtful accounts was approximately $37,000 at June 30, 2018, compared to $35,000 at March 31, 2018.

9

Valuation of inventory

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $63,000 at June 30, 2018 compared to $58,000 at March 31, 2018.

Advertising

The Company's advertising expense consists primarily of Internet marketing and direct mail/print advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related brochures and postcards are produced, distributed, or superseded.

Accounting for income taxes

The Company accounts for income taxes under the provisions of ASC Topic 740 (“Accounting for Income Taxes”), which generally requires recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the Consolidated Financial Statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities, and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.

Results of Operations

The following should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in the Company’s Condensed Consolidated Statements of Comprehensive Income:

	Three Months Ended
	June 30,
	2018			2017
Sales		100.0	%		100.0	%
Cost of sales		65.7			65.5
Gross profit		34.3			34.5
Operating expenses:
General and administrative		7.9			7.8
Advertising		7.7			7.9
Depreciation		0.7			0.7
Total operating expenses		16.3			16.4
Income from operations		18.0			18.1
Total other income		0.8			0.4
Income before provision for income taxes		18.8			18.5
Provision for income taxes		4.4			6.9
Net income		14.4	%		11.6	%

10

Three Months Ended June 30, 2018 Compared With Three Months Ended June 30, 2017

Sales

Sales increased by approximately $7.7 million, or 9.7%, to approximately $87.4 million for the quarter ended June 30, 2018, from approximately $79.7 million for the quarter ended June 30, 2017. The increase in sales for the three months ended June 30, 2018 was primarily due to increased new order and reorder sales. The Company acquired approximately 169,000 new customers for both the quarters ended June 30, 2018 and 2017. The following table illustrates sales by various sales classifications:

Three Months Ended June 30,
Sales (In thousands)	2018		%			2017		%			$ Variance		% Variance
Reorder Sales	$	71,501		81.8	%	$	64,465		80.9	%	$	7,036		10.9	%
New Order Sales		15,889		18.2	%		15,192		19.1	%		697		4.6	%
Total Net Sales	$	87,390		100.0	%	$	79,657		100.0	%	$	7,733		9.7	%
Internet Sales	$	74,320		85.0	%	$	66,647		83.7	%	$	7,673		11.5	%
Contact Center Sales		13,070		15.0	%		13,010		16.3	%		60		0.5	%
Total Net Sales	$	87,390		100.0	%	$	79,657		100.0	%	$	7,733		9.7	%

Going forward sales may be adversely affected due to increased competition and consumers giving more consideration to price. No guarantees can be made that sales will continue to grow in the future. The majority of our product sales are affected by the seasons, due to the seasonality of mainly heartworm, and flea and tick medications. For the quarters ended June 30, September 30, December 31, and March 31 of Fiscal 2018, the Company’s sales were approximately 29%, 24%, 22%, and 25%, respectively.

Cost of sales

Cost of sales increased by approximately $5.2 million, or 10.0%, to approximately $57.4 million for the quarter ended June 30, 2018, from approximately $52.2 million for the quarter ended June 30, 2017. The increase in cost of sales is directly related to the increase in sales during the quarter ended June 30, 2018. As a percent of sales, the cost of sales was 65.7% and 65.5% for the quarters ended June 30, 2018 and 2017, respectively. The cost of sales percentage increase is mainly attributed to increased product costs and additional discounts given to customers to increase sales during the quarter.

Gross profit

Gross profit increased by approximately $2.5 million, or 9.1%, to approximately $30.0 million for the quarter ended June 30, 2018, from approximately $27.5 million for the quarter ended June 30, 2017. The increase in gross profit is directly related to the increase in sales during the quarter ended June 30, 2018. Gross profit as a percentage of sales was 34.3% and 34.5% for the quarters ended June 30, 2018 and 2017, respectively. The gross profit percentage decrease is mainly attributed to increased product costs and additional discounts given to customers to increase sales during the quarter.

General and administrative expenses

General and administrative expenses increased by approximately $708,000, or 11.4%, to approximately $6.9 million for the quarter ended June 30, 2018, from approximately $6.2 million for the quarter ended June 30, 2017. The increase in general and administrative expenses for the three months ended June 30, 2018 was primarily due to the following: a $384,000 increase in payroll expenses due to increased sales, with about $157,000 directly related to increased stock compensation expense; a $169,000 increase in bank service fees; an $80,000 increase in professional fees; a $65,000 increase in property expenses; and a $10,000 net increase in other expenses, which includes licenses and fees and travel related expenses.

11

Advertising expenses

Advertising expenses increased by approximately $415,000, or 6.6%, to approximately $6.7 million for the quarter ended June 30, 2018, from approximately $6.3 million for the quarter ended June 30, 2017. The increase in advertising expenses for the quarter was intended to stimulate sales and acquire new customers. The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $40 for the quarter ended June 30, 2018 compared to $37 for the quarter ended June 30, 2017. Advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, advertising spending, and price competition. Historically, the advertising environment fluctuates due to supply and demand. A more favorable advertising environment may positively impact future new order sales, whereas a less favorable advertising environment may negatively impact future new order sales.

As a percentage of sales, advertising expense was 7.7% and 7.9% for the quarters ended June 30, 2018 and 2017, respectively. The decrease in advertising expense as a percentage of total sales for the quarter ended June 30, 2018 can be mainly attributed to increased sales. The Company currently anticipates advertising as a percentage of sales to be between approximately 7.0% and 8.0% for fiscal 2019. However, the advertising percentage will fluctuate quarter to quarter due to seasonality and advertising availability.

Depreciation

Depreciation expense increased by approximately $25,000, to approximately $556,000 for the quarter ended June 30, 2018, compared to approximately $531,000 for the quarter ended June 30, 2017. This increase to depreciation expense for the quarter ended June 30, 2018 can be attributed to an increase in new property and equipment additions during the quarter.

Other income

Other income increased by approximately $372,000, to approximately $696,000 for the quarter ended June 30, 2018 compared to approximately $324,000 for the quarter ended June 30, 2017. The increase to other income for the quarter ended June 30, 2018 is primarily related to increased interest income, with additional increases to rental and advertising revenue. Interest income may decrease in the future as the Company utilizes its cash balances on its share repurchase plan, with approximately $10.2 million remaining as of June 30, 2018, on any quarterly dividend payment, or on its operating activities.

Provision for income taxes

For the quarters ended June 30, 2018 and 2017, the Company recorded an income tax provision of approximately $3.9 million and $5.5 million, respectively. The effective tax rate for the quarter ended June 30, 2018 was approximately 23.5% compared to 37.1% for the quarter ended June 30, 2017. The decrease in the income tax provision and the effective tax rate for the quarter ended June 30, 2018 are directly related to a decrease in the federal tax rate from 35.0% to 21.0% pursuant to the Tax Cuts and Jobs Act of 2017 (“2017 Act”). The Company estimates its effective rate will be approximately 24.0% for fiscal 2019.

Liquidity and Capital Resources

     The Company’s working capital at June 30, 2018 and March 31, 2018 was $95.4 million and $87.1 million, respectively. The $8.3 million increase in working capital was primarily attributable to cash flow generated from operations, offset by dividends paid in the period. Net cash provided by operating activities was $22.0 million and $13.9 million for the three months ended June 30, 2018 and 2017, respectively. This increase is mainly attributed to an increase in net income and a much greater increase in accounts payable for the quarter ended June 30, 2018, compared to the quarter ended June 30, 2017. Net cash used in investing activities increased to $306,000 for the three months ended June 30, 2018, compared to $43,000 used in investing activities for the three months ended June 30, 2017. This change in investing activities is related to increased property additions related to the Company’s new corporate headquarters and distribution facility in Delray Beach, Florida. Net cash used in financing activities was $5.1 million for the quarter ended June 30, 2018 compared to $4.1 million for the quarter ended June 30, 2017, which represented an increase in the dividend paid in the quarter ended June 30, 2018.

12

At June 30, 2018 the Company had approximately $10.2 million remaining under the Company’s share repurchase plan. On July 23, 2018 our Board of Directors declared an increased $0.27 per share dividend. The Board established an August 3, 2018 record date and an August 10, 2018 payment date. Depending on future market conditions the Company may utilize its cash and cash equivalents on the remaining balance of its current share repurchase plan, on quarterly dividends, or on its operating activities.

At June 30, 2018 the Company had no outstanding lease commitments. We are not currently bound by any long or short term agreements for the purchase or lease of capital expenditures. Any material amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately provide for any increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. Presently, we have approximately $750,000 forecasted for capital expenditures for the remainder of fiscal 2019, which will be funded through cash from operations. The Company’s primary source of working capital is cash from operations. The Company presently has no need for alternative sources of working capital, and has no commitments or plans to obtain additional capital.

Off-Balance Sheet Arrangements

The Company had no off-balance sheet arrangements at June 30, 2018.

Cautionary Statement Regarding Forward-Looking Information

Certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this quarterly report. When used in this quarterly report on Form 10-Q, "PetMed Express," "1-800-PetMeds," "PetMeds," "PetMed," "PetMeds.com," "PetMed.com," "PetMed Express.com," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and our subsidiaries.

ITEM 3.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices. Our financial instruments include cash and cash equivalents, short term investments, accounts receivable, and accounts payable. The book values of cash equivalents, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments. Interest rates affect our return on excess cash and investments. At June 30, 2018, we had $94.6 million in cash and cash equivalents, and the majority of our cash and cash equivalents and investments generate interest income based on prevailing interest rates. A significant change in interest rates would impact the amount of interest income generated from our excess cash and investments. It would also impact the market value of our investments. Our investments are subject to market risk, primarily interest rate and credit risk. Our investments are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors. Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by restricting our investments to high-quality debt instruments with both short and long term maturities. We do not hold any derivative financial instruments that could expose us to significant market risk. At June 30, 2018, we had no debt obligations.

13

ITEM 4.   CONTROLS AND PROCEDURES.

The Company’s management, including our Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15 promulgated under the Securities Exchange Act of 1934, as amended) as of the quarter ended June 30, 2018, the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective such that the information relating to our Company, including our consolidated subsidiaries, required to be disclosed by the Company in reports that it files or submits under the Exchange Act: (1) is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and (2) is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. The adoption of Accounting Standards Codification 606, Revenue from Contracts with Customers, did not require significant changes in our internal controls and procedures over financial reporting and disclosures. However, we made enhancements to existing internal controls and procedures to ensure compliance with the new guidance.

part ii - other information

ITEM 1.     LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, results of operations, and trading price of our common stock. Please refer to our Annual Report on Form 10-K for the fiscal year ended March 31, 2018 for additional information concerning these and other uncertainties that could negatively impact the Company.

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

The Company did not make any sales of unregistered securities during the first quarter of fiscal 2019.

Issuer Purchases of Equity Securities

None.

ITEM 3.    DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.    MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5.    OTHER INFORMATION.

None.

14

ITEM 6.     EXHIBITS

The following exhibits are filed as part of this report.

31.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities Exchange Act of 1934, as amended (filed herewith to Exhibit 31.1 of the Registrant’s Report on Form 10-Q for the quarter ended June 30, 2018, Commission File No. 000-28827).

31.2 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities Exchange Act of 1934, as amended (filed herewith to Exhibit 31.2 of the Registrant’s Report on Form 10-Q for the quarter ended June 30, 2018, Commission File No. 000-28827).

32.1 Certification Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith to Exhibit 32.1 of the Registrant’s Report on Form 10-Q for the quarter ended June 30, 2018, Commission File No. 000-28827).

15

signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PETMED EXPRESS, INC.
(The “Registrant”)
Date: July 31, 2018
By:	/s/ Menderes Akdag
	Menderes Akdag
	Chief Executive Officer and President
	(principal executive officer)
By:	/s/ Bruce S. Rosenbloom
	Bruce S. Rosenbloom
	Chief Financial Officer
	(principal financial and accounting officer)

16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________

PETMED EXPRESS, INC

_______________________

FORM 10-Q

FOR THE QUARTER ENDED:

JUNE 30, 2018

_______________________

EXHIBITS

_______________________

EXHIBIT INDEX

Exhibit Number	Description	Number of Pages in Original Document	Incorporated By Reference
31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	1	**
31.2	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	1	**
32.1	Certification Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	1	**

101.INS***      XBRL Instance

101.SCH***     XBRL Taxonomy Extension Schema

101.CAL***     XBRL Taxonomy Extension Calculation

101.DEF***     XBRL Taxonomy Extension Definition

101.LAB***     XBRL     Taxonomy Extension Labels

101.PRE***     XBRL     Taxonomy Extension Presentation

**                     Filed herewith

***                   XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections

EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Menderes Akdag, certify that:

1. I have reviewed this report on Form 10-Q for the quarter ended June 30, 2018 of PetMed Express, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

July 31, 2018

By: /s/ Menderes Akdag

Menderes Akdag

Chief Executive Officer and President

EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bruce S. Rosenbloom, certify that:

1. I have reviewed this report on Form 10-Q for the quarter ended June 30, 2018 of PetMed Express, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

July 31, 2018

By: /s/ Bruce S. Rosenbloom

Bruce S. Rosenbloom

Chief Financial Officer

EX-32.1

 Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Menderes Akdag, and I, Bruce S. Rosenbloom, each certify to the best of our knowledge, based upon a review of the report on Form 10-Q for the quarter ended June 30, 2018 (the “Report”) of the Registrant, that:

(1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: July 31, 2018
By:	/s/ Menderes Akdag
Menderes Akdag
Chief Executive Officer and President
By:	/s/ Bruce S. Rosenbloom
Bruce S. Rosenbloom
Chief Financial Officer

XML

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2018	Jul. 31, 2018
Document Information [Line Items]
Entity Registrant Name	PETMED EXPRESS INC
Entity Central Index Key	0001040130
Trading Symbol	pets
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		20,685,555
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018
Current assets:
Cash and cash equivalents	$ 94,561	$ 77,936
Accounts receivable, less allowance for doubtful accounts of $37 and $35, respectively	2,431	2,292
Inventories - finished goods	25,046	23,337
Prepaid expenses and other current assets	1,278	882
Prepaid income taxes		788
Total current assets	123,316	105,235
Noncurrent assets:
Property and equipment, net	28,491	28,741
Intangible assets	860	860
Total noncurrent assets	29,351	29,601
Total assets	152,667	134,836
Current liabilities:
Accounts payable	21,182	15,274
Accrued expenses and other current liabilities	3,526	2,835
Income taxes payable	3,247
Total current liabilities	27,955	18,109
Deferred tax liabilities	831	996
Total liabilities	28,786	19,105
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share	9	9
Common stock, $.001 par value, 40,000 shares authorized; 20,601 and 20,601 shares issued and outstanding, respectively	21	21
Additional paid-in capital	10,100	9,381
Retained earnings	113,751	106,320
Total shareholders' equity	123,881	115,731
Total liabilities and shareholders' equity	$ 152,667	$ 134,836

XML

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2018	Mar. 31, 2018
Allowance for doubtful accounts	$ 37	$ 35
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, liquidation preference (in dollars per share)	$ 4	$ 4
Preferred stock, shares issued (in shares)	3	3
Preferred stock, shares outstanding (in shares)	3	3
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	40,000	40,000
Common stock, shares issued (in shares)	20,601	20,601
Common stock, shares outstanding (in shares)	20,601	20,601

XML

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Sales	$ 87,390	$ 79,657
Cost of sales	57,436	52,192
Gross profit	29,954	27,465
Operating expenses:
General and administrative	6,934	6,226
Advertising	6,707	6,292
Depreciation	556	531
Total operating expenses	14,197	13,049
Income from operations	15,757	14,416
Other income:
Interest income, net	379	83
Other, net	317	241
Total other income	696	324
Income before provision for income taxes	16,453	14,740
Provision for income taxes	3,871	5,464
Net income	12,582	9,276
Comprehensive income	$ 12,582	$ 9,276
Net income per common share:
Basic (in dollars per share)	$ 0.62	$ 0.46
Diluted (in dollars per share)	$ 0.62	$ 0.45
Basic (in shares)	20,408	20,293
Diluted (in shares)	20,449	20,448
Cash dividends declared per common share (in dollars per share)	$ 0.25	$ 0.20

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income	$ 12,582	$ 9,276
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	556	531
Share based compensation	719	494
Deferred income taxes	(165)	(104)
Bad debt expense	32	28
(Increase) decrease in operating assets and increase in liabilities:
Accounts receivable	(171)	(279)
Inventories - finished goods	(1,709)	(2,804)
Prepaid income taxes	788
Prepaid expenses and other current assets	(396)	(494)
Accounts payable	5,908	984
Accrued expenses and other current liabilities	643	696
Income taxes payable	3,247	5,568
Net cash provided by operating activities	22,034	13,896
Cash flows from investing activities:
Purchases of property and equipment	(306)	(43)
Net cash used in investing activities	(306)	(43)
Cash flows from financing activities:
Dividends paid	(5,103)	(4,058)
Net cash used in financing activities	(5,103)	(4,058)
Net increase in cash and cash equivalents	16,625	9,795
Cash and cash equivalents, at beginning of period	77,936	58,730
Cash and cash equivalents, at end of period	94,561	68,525
Supplemental disclosure of cash flow information:
Dividends payable in accrued expenses	$ 288	$ 263

XML

Note 1 - Summary of Significant Accounting Policies

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

Note

1:

Summary of Significant Accounting Policies

Organization

PetMed Express, Inc. and subsidiaries, d/b/a

1

-

800

-PetMeds (the “Company”), is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The Company offers consumers an attractive alternative for obtaining pet medications in terms of convenience, price, and speed of delivery. The Company markets its products through national advertising campaigns, which aim to increase the recognition of the

“1

-

800

-PetMeds” brand name, and “PetMeds” family of trademarks, increase traffic on its website at

www.1800petmeds.com

, acquire new customers, and maximize repeat purchases. The majority of the Company’s sales are to residents in the United States. The Company’s corporate headquarters and distribution facility is located in Delray Beach, Florida. The Company’s fiscal year end is

March 31,

and references herein to fiscal

2019

or fiscal

2018

refer to the Company's fiscal years ending

March 31, 2019

and

2018,

respectively.

Basis of Presentation and Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form

10

-Q and, therefore, do

not

include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at

June 30, 2018,

the Statements of Comprehensive Income for the

three

months ended

June 30, 2018

and

2017,

and Cash Flows for the

three

months ended

June 30, 2018

and

2017.

The results of operations for the

three

months ended

June 30, 2018

are

not

necessarily indicative of the operating results expected for the fiscal year ending

March 31, 2019.

These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s annual report on Form

10

-K for the fiscal year ended

March 31, 2018.

The Condensed Consolidated Financial Statements include the accounts of PetMed Express, Inc. and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates

The preparation of Condensed Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.

Recent Accounting Pronouncements

In

May 2014,

the Financial Accounting Standards Board (“FASB”) issued ASU

2014

-

09,

“Revenue from Contracts with Customers” (“ASC

606”

). ASC

606

clarifies the accounting for revenue arising from contracts with customers and specifies the disclosures that an entity should include in its financial statements. During

2016,

the FASB issued certain amendments to the standard relating to the principal versus agent guidance, accounting for licenses of intellectual property and identifying performance obligations as well as the guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The Company adopted ASC

606

using the modified retrospective method on

April 1, 2018.

Therefore, the comparative financial information has

not

been restated and continues to be reported under the accounting standards in effect for those periods.

The Company evaluated only contracts

not

completed at the date of initial application for each of the

five

steps in ASC

606,

which are as follows:

1

) Identify the contract with the customer;

2

) Identify the performance obligations in the contract;

3

) Determine the transaction price;

4

) Allocate the transaction price to the performance obligations; and

5

) Recognize revenue when (or as) performance obligations are satisfied. The effect of initially applying ASC

606

did

not

result in an opening balance adjustment to retained earnings or any other Balance Sheet accounts because the Company: (

1

) identified similar performance obligations under ASC

606

as compared with deliverables and separate units of account previously identified; (

2

) determined the transaction price to be consistent; and (

3

) concluded that revenue is recorded at the same point in time, upon shipment under both ASC

605

and ASC

606.

Additionally, the Company concluded that the accounting for fulfillment costs or costs incurred to obtain a contract is unchanged by the adoption of ASC

606.

The adoption of ASC

606

did

not

require significant changes in our internal controls and procedures over financial reporting and disclosures. However, we made enhancements to existing internal controls and procedures to ensure compliance with the new guidance.

In

February 2016,

the FASB issued guidance on leases which supersedes the current lease guidance. The core principle requires lessees to recognize the assets and liabilities that arise from nearly all leases in the statement of financial position. Accounting applied by lessors will remain largely consistent with previous guidance. Additional changes are expected to align lessor accounting with the revised lessee model and the FASB’s revenue recognition guidance. The amendments are effective for fiscal years beginning after

December 15, 2018,

including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements. We do

not

expect the standard to have a material impact on our consolidated financial statements.

The Company does

not

believe that any other recently issued, but

not

yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

XML

Note 2 - Revenue Recognition

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

Note

2:

Revenue Recognition

The Company generates revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain

one

performance obligation, which is delivery of the product; customer care and support is deemed

not

to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however

not

considered a key judgment. There are

no

amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Outbound shipping and handling fees are an accounting policy election, and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.

The Company disaggregates revenue in the following

two

categories: (

1

) Reorder revenue vs new order revenue, and (

2

) Internet revenue vs. contact center revenue. The following table illustrates revenue by various classifications:

Three Months Ended June 30,
Revenue (In thousands)	2018		%			2017		%			$ Variance		% Variance
Reorder Sales	$	71,501		81.8	%	$	64,465		80.9	%	$	7,036		10.9	%
New Order Sales		15,889		18.2	%		15,192		19.1	%		697		4.6	%
Total Net Sales	$	87,390		100.0	%	$	79,657		100.0	%	$	7,733		9.7	%
Internet Sales	$	74,320		85.0	%	$	66,647		83.7	%	$	7,673		11.5	%
Contact Center Sales		13,070		15.0	%		13,010		16.3	%		60		0.5	%
Total Net Sales	$	87,390		100.0	%	$	79,657		100.0	%	$	7,733		9.7	%

The majority of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in

two

to

three

banking days. Credit card sales minimize the accounts receivable balances relative to sales. The Company had

no

material contract asset or contract liability balances as of

June 30, 2018

or

March 31, 2018.

XML

Note 3 - Net Income Per Share

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

Note

3

:

Net Income Per Share

In accordance with the provisions of ASC Topic

260

(“

Earnings Per Share

”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock and convertible preferred shares issued by the Company represent the only dilutive effect reflected in the diluted weighted average shares outstanding. The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented (in thousands, except for per share amounts):

	Three Months Ended June 30,
	2018		2017
Net income (numerator):
Net income	$	12,582	$	9,276
Shares (denominator):
Weighted average number of common shares outstanding used in basic computation		20,408		20,293
Common shares issuable upon vesting of restricted stock		31		145
Common shares issuable upon conversion of preferred shares		10		10
Shares used in diluted computation		20,449		20,448
Net income per common share:
Basic	$	0.62	$	0.46
Diluted	$	0.62	$	0.45

At

June 30, 2018,

77,350

shares of common restricted stock were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted net income per common share. At

June 30, 2017,

all common restricted stock was included in the diluted net income per common share computation.

XML

Note 4 - Stock-based Compensation

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note

4

:

Stock-Based Compensation

The Company records compensation expense associated with restricted stock in accordance with ASC Topic

718

(

“Share Based Payment

”

) (ASU

2016

-

09

). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses. The Company had

974,609

restricted common shares issued under the

2006

Employee Equity Compensation Restricted Stock Plan (

“2006

Employee Plan”),

47,350

restricted common shares issued under the

2016

Employee Equity Compensation Restricted Stock Plan (

“2016

Employee Plan” and collectively referred to with the

2006

Employee Plan as the “Employee Plans”),

272,000

restricted common shares issued under the

2006

Outside Director Equity Compensation Restricted Stock Plan (

“2006

Director Plan”), and

60,000

restricted common shares issued under the

2015

Outside Director Equity Compensation Restricted Stock Plan (

“2015

Director Plan”, and collectively referred to with the

2006

Director Plan as the “Director Plans”) at

June 30, 2018,

all shares of which were issued subject to a restriction or forfeiture period that lapses ratably on the first, second, and

third

anniversaries of the date of grant, and the fair value of which is being amortized over the

three

-year restriction period.

The Company did

not

issue any shares of restricted stock during the quarter. For the quarters ended

June 30, 2018

and

2017,

the Company recognized

$719,000

and

$494,000,

respectively, of compensation expense related to the Employee and Director Plans. At

June 30, 2018

and

2017,

there was

$3.7

million and

$2.8

million of unrecognized compensation cost related to the non-vested restricted stock awards, respectively, which is expected to be recognized over the next

three

years. At

June 30, 2018

and

2017,

there were

193,000

and

232,000

non-vested restricted shares, respectively.

XML

Note 5 - Fair Value

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note

5

:

Fair Value

The Company carries cash and cash equivalents and investments at fair value in the Condensed Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic

820

(“Fair Value Measurements”) establishes a

three

-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 

1

- Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 

2

- Include other inputs that are directly or indirectly observable in the marketplace.

Level 

3

- Unobservable inputs which are supported by little or

no

market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At

June 30, 2018,

the Company had invested the majority of its

$94.6

million cash and cash equivalents balance in money market funds which are classified within level

1.

XML

Note 6 - Commitments and Contingencies

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Note

6

: Commitments and Contingencies

The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be

no

assurances made that other states will

not

attempt to take similar actions against the Company in the future. The Company initiates litigation to protect its trade or service marks. There can be

no

assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred.

XML

Note 7 - Changes in Shareholders' Equity

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Note

7

: Changes in

S

hare

holders’

Equity:

Changes in shareholders’ equity for the

three

months ended

June 30, 2018

is summarized below (in thousands):

	Additional
	Paid-In		Retained
	Capital		Earnings
Beginning balance at March 31, 2018:	$	9,381	$	106,320
Share based compensation		719		-
Dividends declared		-		(5,151	)
Net income		-		12,582
Ending balance at June 30, 2018:	$	10,100	$	113,751

No

shares of treasury stock were purchased or retired in the

three

months ended

June 30, 2018

and

2017.

XML

Note 8 - Income Taxes

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]

Note

8

: Income Taxes

For the quarters ended

June 30, 2018

and

2017,

the Company recorded an income tax provision of approximately

$3.9

million and

$5.5

million, respectively. The effective tax rate for the quarter ended

June 30, 2018

was approximately

23.5%

compared to

37.1%

for the quarter ended

June 30, 2017.

The decrease in the income tax provision and the effective tax rate for the quarter ended

June 30, 2018

are directly related to a decrease in the federal tax rate from

35.0%

to

21.0%

pursuant to the Tax Cuts and Jobs Act of

2017

(

“2017

Act”).

XML

Note 9 - Subsequent Events

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Subsequent Events [Text Block]

Note

9

: Su

b

sequent Event

s

On

July 23, 2018

,

the Board of Directors declared an increased quarterly dividend of

$0.27

per share. The Board established an

August 3, 2018

record date and an

August 10, 2018

payment date. Based on the outstanding share balance as of

July 31, 2018

the Company estimates the dividend payable to be approximately

$5.6

million.

On

July 27, 2018,

the Board of Directors approved the issuance of

47,450

restricted shares to certain employees of the Company, pursuant to the

2016

Employee Plan and the issuance of

37,500

restricted shares to the independent directors, pursuant to the

2015

Director Plan.

XML

Significant Accounting Policies (Policies)

3 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis Of Presentation and Consolidation [Policy Text Block]

Basis of Presentation and Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form

10

-Q and, therefore, do

not

include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at

June 30, 2018,

the Statements of Comprehensive Income for the

three

months ended

June 30, 2018

and

2017,

and Cash Flows for the

three

months ended

June 30, 2018

and

2017.

The results of operations for the

three

months ended

June 30, 2018

are

not

necessarily indicative of the operating results expected for the fiscal year ending

March 31, 2019.

These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s annual report on Form

10

-K for the fiscal year ended

March 31, 2018.

The Condensed Consolidated Financial Statements include the accounts of PetMed Express, Inc. and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of Condensed Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In

May 2014,

the Financial Accounting Standards Board (“FASB”) issued ASU

2014

-

09,

“Revenue from Contracts with Customers” (“ASC

606”

). ASC

606

clarifies the accounting for revenue arising from contracts with customers and specifies the disclosures that an entity should include in its financial statements. During

2016,

the FASB issued certain amendments to the standard relating to the principal versus agent guidance, accounting for licenses of intellectual property and identifying performance obligations as well as the guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The Company adopted ASC

606

using the modified retrospective method on

April 1, 2018.

Therefore, the comparative financial information has

not

been restated and continues to be reported under the accounting standards in effect for those periods.

The Company evaluated only contracts

not

completed at the date of initial application for each of the

five

steps in ASC

606,

which are as follows:

1

) Identify the contract with the customer;

2

) Identify the performance obligations in the contract;

3

) Determine the transaction price;

4

) Allocate the transaction price to the performance obligations; and

5

) Recognize revenue when (or as) performance obligations are satisfied. The effect of initially applying ASC

606

did

not

result in an opening balance adjustment to retained earnings or any other Balance Sheet accounts because the Company: (

1

) identified similar performance obligations under ASC

606

as compared with deliverables and separate units of account previously identified; (

2

) determined the transaction price to be consistent; and (

3

) concluded that revenue is recorded at the same point in time, upon shipment under both ASC

605

and ASC

606.

Additionally, the Company concluded that the accounting for fulfillment costs or costs incurred to obtain a contract is unchanged by the adoption of ASC

606.

The adoption of ASC

606

did

not

require significant changes in our internal controls and procedures over financial reporting and disclosures. However, we made enhancements to existing internal controls and procedures to ensure compliance with the new guidance.

In

February 2016,

the FASB issued guidance on leases which supersedes the current lease guidance. The core principle requires lessees to recognize the assets and liabilities that arise from nearly all leases in the statement of financial position. Accounting applied by lessors will remain largely consistent with previous guidance. Additional changes are expected to align lessor accounting with the revised lessee model and the FASB’s revenue recognition guidance. The amendments are effective for fiscal years beginning after

December 15, 2018,

including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements. We do

not

expect the standard to have a material impact on our consolidated financial statements.

The Company does

not

believe that any other recently issued, but

not

yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

XML

Note 2 - Revenue Recognition (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Disaggregation of Revenue [Table Text Block]

Three Months Ended June 30,
Revenue (In thousands)	2018		%			2017		%			$ Variance		% Variance
Reorder Sales	$	71,501		81.8	%	$	64,465		80.9	%	$	7,036		10.9	%
New Order Sales		15,889		18.2	%		15,192		19.1	%		697		4.6	%
Total Net Sales	$	87,390		100.0	%	$	79,657		100.0	%	$	7,733		9.7	%
Internet Sales	$	74,320		85.0	%	$	66,647		83.7	%	$	7,673		11.5	%
Contact Center Sales		13,070		15.0	%		13,010		16.3	%		60		0.5	%
Total Net Sales	$	87,390		100.0	%	$	79,657		100.0	%	$	7,733		9.7	%

XML

Note 3 - Net Income Per Share (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended June 30,
	2018		2017
Net income (numerator):
Net income	$	12,582	$	9,276
Shares (denominator):
Weighted average number of common shares outstanding used in basic computation		20,408		20,293
Common shares issuable upon vesting of restricted stock		31		145
Common shares issuable upon conversion of preferred shares		10		10
Shares used in diluted computation		20,449		20,448
Net income per common share:
Basic	$	0.62	$	0.46
Diluted	$	0.62	$	0.45

XML

Note 7 - Changes in Shareholders' Equity (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Stockholders Equity [Table Text Block]

	Additional
	Paid-In		Retained
	Capital		Earnings
Beginning balance at March 31, 2018:	$	9,381	$	106,320
Share based compensation		719		-
Dividends declared		-		(5,151	)
Net income		-		12,582
Ending balance at June 30, 2018:	$	10,100	$	113,751

XML

Note 2 - Revenue Recognition (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Contract with Customer, Liability, Total	$ 0	$ 0
Contract with Customer, Asset, Net, Total	$ 0	$ 0
Minimum [Member]
Credit Card Sales, Cash Settlement Period	2 days
Maximum [Member]
Credit Card Sales, Cash Settlement Period	3 days

XML

Note 2 - Revenue Recognition - Disaggregation Of Revenue by Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Revenues	$ 87,390	$ 79,657
Revenues	100.00%	100.00%
Revenues	$ 7,733
Revenues	9.70%
Internet [Member]
Revenues	$ 74,320	$ 66,647
Revenues	85.00%	83.70%
Revenues	$ 7,673
Revenues	11.50%
Contact Center [Member]
Revenues	$ 13,070	$ 13,010
Revenues	15.00%	16.30%
Revenues	$ 60
Revenues	0.50%
Reorder Customer [Member]
Revenues	$ 71,501	$ 64,465
Revenues	81.80%	80.90%
Revenues	$ 7,036
Revenues	10.90%
New Order Customer [Member]
Revenues	$ 15,889	$ 15,192
Revenues	18.20%	19.10%
Revenues	$ 697
Revenues	4.60%

XML

Note 3 - Net Income Per Share (Details Textual)	3 Months Ended
	Jun. 30, 2018 shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	77,350

XML

Note 3 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Net income (numerator):
Net income	$ 12,582	$ 9,276
Shares (denominator):
Weighted average number of common shares outstanding used in basic computation (in shares)	20,408	20,293
Common shares issuable upon vesting of restricted stock (in shares)	31	145
Common shares issuable upon conversion of preferred shares (in shares)	10	10
Shares used in diluted computation (in shares)	20,449	20,448
Net income per common share
Basic (in dollars per share)	$ 0.62	$ 0.46
Diluted (in dollars per share)	$ 0.62	$ 0.45

XML

Note 4 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	0
2006 Employee Equity Compensation Restricted Stock Plan (the "Employee Plan") [Member] | Restricted Stock [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	974,609
2016 Employee Equity Compensation Restricted Stock Plan [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	47,350
2006 Outside Director Equity Compensation Restricted Stock Plan (the "Director Plan") [Member] | Restricted Stock [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	272,000
2015 Outside Director Equity Compensation Restricted Stock Plan ("2015 Director Plan") [Member] | Restricted Stock [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	60,000
Employee and Director Plans [Member] | Restricted Stock [Member]
Allocated Share-based Compensation Expense, Total	$ 719,000	$ 494,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	193,000	232,000
Employee and Director Plans [Member] | Restricted Stock [Member] | General and Administrative Expense [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 3,700,000	$ 2,800,000

XML

Note 5 - Fair Value (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 94,561	$ 77,936	$ 68,525	$ 58,730

XML

Note 7 - Changes in Shareholders' Equity (Details Textual) - shares shares in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Treasury Stock, Shares, Acquired	0	0

XML

Note 7 - Changes in Shareholders' Equity - Schedule of Changes in Shareholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Balance	$ 115,731
Net income	12,582	$ 9,276
Balance	123,881
Additional Paid-in Capital [Member]
Balance	9,381
Share based compensation	719
Dividends declared
Net income
Balance	10,100
Retained Earnings [Member]
Balance	106,320
Share based compensation
Dividends declared	(5,151)
Net income	12,582
Balance	$ 113,751

XML

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Income Tax Expense (Benefit), Total	$ 3,871	$ 5,464
Effective Income Tax Rate Reconciliation, Percent, Total	23.50%	37.10%

XML

Note 9 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended
	Jul. 27, 2018	Jul. 23, 2018	Jun. 30, 2018
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			0
Subsequent Event [Member]
Dividends Payable, Date Declared		Jul. 23, 2018
Dividends Payable, Amount Per Share		$ 0.27
Dividends Payable, Date of Record		Aug. 03, 2018
Dividends Payable, Date to be Paid		Aug. 10, 2018
Dividends Payable		$ 5.6
Subsequent Event [Member] | 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	47,450
Subsequent Event [Member] | 2015 Outside Director Equity Compensation Restricted Stock Plan ("2015 Director Plan") [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	37,500